Navigation Links
New Colorectal Cancer Screening Coverage to Drive US Gastrointestinal Endoscopy Device Market to Almost $2.2 Billion by 2014
Date:8/19/2010

WALTHAM, Mass., Aug. 19 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, new coverage instituted under the Patient Protection and Affordable Care Act of 2010 will remove the financial disincentives associated with colorectal cancer screening for a large segment of the US population. As a result of these changes in reimbursement, a growing number of colorectal cancer screening procedures will be performed through 2014, driving sales of many gastrointestinal endoscopy devices, including videoscopes and biopsy forceps.

Under the health care act, all new health insurance policies must cover preventative exams, including colonoscopies, without charging out-of-pocket fees such as copayments or deductibles. All Medicare patients will therefore have colorectal cancer screening colonoscopies fully covered as of January 1, 2011. This expanded coverage of colorectal cancer screening procedures will increase the number of colonoscopies performed over the next five years. Sales of devices used in the procedures, such as colonoscopes and biopsy forceps, will also rise to meet this growing demand for colorectal cancer screening. Although colonoscopy volumes dipped in 2009 during the recession, they are climbing again and will continue to rise as increased medical insurance coverage encourages more Americans to undergo screening.

"At the height of the economic downturn, many Americans declined to undergo colorectal cancer screening because they lost insurance coverage for it or they felt that paying for a diagnostic procedure when they did not have any symptoms was not a priority for them in economically uncertain times," said Sara Scharf, Ph D, Analyst at MRG. "As this new coverage is put in place, patients will increasingly get screened for colorectal cancer."

MRG's new report, US Markets for Gastrointestinal Endoscopy Devices 2010, now includes more segments, detailed competitor coverage, and insights into trends than ever before. The report provides a thorough analysis of procedural trending, emerging markets, competing and complementary procedures, and revenue growth for the major gastrointestinal endoscopy devices in the US, including videoscopes, enteral feeding devices, endoscopic retrograde cholangiopancreatography devices, hemostasis devices, biopsy forceps, stents, virtual colonoscopy systems, esophageal dilation balloons, capsule endoscopes, polypectomy snares, and retrieval devices. For the first time, this report includes market analyses of enteral feeding giving sets, nasogastric tubes, colonic and duodenal stents, and Barrett's esophagus ablation devices.  

About Millennium Research GroupMillennium Research Group (www.MRG.net), a Decision Resources, Inc. company (www.DecisionResourcesInc.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer behavior tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Amy KrohnMillennium Research Group416-364-7776 ext. 101akrohn@mrg.netChris ComfortDecision Resources, Inc. 781-296-2597ccomfort@dresources.com
'/>"/>

SOURCE Millennium Research Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
2. For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer
5. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
6. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
7. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
8. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
9. ARUP Laboratories Applauds FDAs Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
10. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
11. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 LG Innotek today announced that the company ... As its sterilization performance is 1.5 times higher than the competitor,s ... rays in the range of 200 -- 280nm, allowing it to be ... destroying their DNA. LG Innotek,s product emits UV in the range ... Until ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Cardiac Prosthetic Devices Market ... the next decade to reach approximately $8.9 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:2/23/2017)... 23, 2017 Tillotts Pharma is ... Berlin office was opened in January ... The portfolio includes Entocort ® for the treatment ... of ulcerative colitis, and VistaPrep ® for bowel ... specialty pharmaceutical company focused on the treatment of gastrointestinal ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... CALNOC, the nation’s ... FACPE, will keynote their upcoming conference – Empowerment, Value and Collaboration – in Seattle, ... and CEO of the Virginia Mason Health System in Seattle since 2000. In addition ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Thomas Vas-Don ... and disciplined exercise regime, the author was able to successfully recover. In “ Origin ... relevant information for various sources on the principals of massage, anatomy , ...
(Date:2/22/2017)... Raton, FL (PRWEB) , ... February 22, 2017 , ... ... primarily from deer antler velvet, announced its products are coming soon to Amazon.com, the ... Clint and Shelley Thomson as a means to develop an effective natural treatment for ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... Burlingame, CA (PRWEB) , ... February 22, 2017 ... ... of American adults with chronic conditions reported skipping doses or not filling a ... were uninsured or under-insured, rates of cost-related problems getting medications were 30-60%*. ...
Breaking Medicine News(10 mins):